Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;40(6):721-734.
doi: 10.1007/s10654-025-01239-4. Epub 2025 Jun 9.

Cohort profile: Copenhagen Hospital Biobank-chronic inflammatory disease-inflammatory bowel disease (CHB-CID:IBD) genetic cohort

Behrooz Darbani  1 , Thorsten Brodersen  2 , Anette Liljensøe  3 , Signe Bek Sørensen  3 , Josephine Bjergbæk Olsson-Svendsen  2 , Alfonso Buil  4 , Ahmed Kamal  5 , Andrew J Schork  6 , Anja Poulsen  7 , Bertram Dalskov Kjerulff  8 , Bitten Aagaard  9 , Britta Ørnfelt Lund  10 , Charlotte Siggaard Rittig  11 , Christina Mikkelsen  12   13 , Daniel Millencourt Larsen  14 , David Westergaard  15 , Ditte Rudbeck-Resdal  16 , Dorte Helenius Mikkelsen  4 , Else Randers  17 , Frank Vinholt Schiødt  18 , Hans Jürgen Hoffmann  8   19 , Isabella Friis Jørgensen  20 , Ivan Brandslund  21   22 , Jacob Broder Brodersen  22   23 , Jakob Hjorth von Stemann  12 , Jakob Thaning Bay  2 , Janna Nissen  12 , Jeanette Sørensen  24 , Jens Kjærgaard Boldsen  8   25 , Joseph Dowsett  12 , Josephine Gladov  8   19   26 , Karina Banasik  15   20 , Kathrine Agergård Kaspersen  8 , Katrine Carlsen  27   28 , Khoa Manh Dinh  8   12 , Lauge Kellermann  29 , Lea Arregui Nordahl Christoffersen  2   4 , Liam James Elgaard Quinn  2 , Lise Wegner Thørner  12 , Lone Larsen  24   30 , Luise Aamann  16 , Malene Rohr Andersen  25 , Maria Didriksen  12 , Maria Joanna Alexandraki  31 , Marianne Kragh Thomsen  19   32 , Mette Julsgaard  16   19 , Mette Nyegaard  33 , Michael Schwinn  12 , Mie Topholm-Bruun  34 , Mikael Njai Leite  35 , Morten Lee Halling  36 , Natalia Pedersen  37 , Ole K Bonderup  38 , Palle Duun Rohde  33 , Pernille Dige Ovesen  29 , Ram Benny Dessau  39   40 , Sanaz Saboori  37 , Sofie Holm-Christensen  38   41 , Steffen Bank  42 , Susan Mikkelsen  8 , Thomas Folkmann Hansen  43 , Thomas Werge  4   44 , Niels Qvist  45   46 , Erik Sørensen  12 , Johan Burisch  44   47   48 , Merete Lund Hetland  44   49   50 , Bente Glintborg  44   49   50 , Christian Erikstrup  8   19 , Søren Brunak  20 , Henrik Ullum  51 , Sisse Rye Ostrowski  12   44 , Ole Birger Vesterager Pedersen  2   44 , Vibeke Andersen  3   40   52
Affiliations

Cohort profile: Copenhagen Hospital Biobank-chronic inflammatory disease-inflammatory bowel disease (CHB-CID:IBD) genetic cohort

Behrooz Darbani et al. Eur J Epidemiol. 2025 Jun.

Abstract

The Copenhagen Hospital Biobank-chronic inflammatory disease-inflammatory bowel disease (CHB-CID: IBD) cohort contributes to genetic research in inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Of the 327,084 enrolled and genotyped individuals in the cohort, 10,626 have been diagnosed with IBD as of May 2023. The CHB-CID: IBD cohort includes both patients without IBD and healthy blood donors as control groups. Clinical data is collected from Danish registries and patient records, including details on hospital contacts, co-morbidities, medication, surgical procedures, and laboratory investigations. The cohort features a wide age range (> 18 years), extensive population coverage representative of Danish adults, and validated IBD diagnoses. Finally, the cohort benefits from continuous recruitment and regular updates of clinical information. The aim is to enhance IBD management and ultimately improve patients' quality of life.

Keywords: Crohn’s disease; Faecal Calprotectin; Genetic cohort; Genetic relatedness; Inflammatory bowel disease; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: All personal fees and grants were received outside this work. Anja Poulsen reports research grants and personal fees from Janssen, Takeda, and MSD, personal fees from Bristol Myers Squibb, national coordinator of studies from Agomab, Boehringer Ingelheim and Bristol Myers. Bente Glintborg has received research grants (paid to institution) from AbbVie, Pfizer, BMS, Sandoz. Bente Glintborg chairs the DANBIO steering committee. Jacob Broder Brodersen has received consultation fee from Jansen-Cilag. Johan Burisch reports grants and personal fees from AbbVie, Janssen-Cilag, Takeda, Tillots Pharma, Bristol Myers Squibb, and MSD, personal fees from Celgene, Pfizer, Samsung Bioepis, Pharmacosmos, Ferring, Galapagos, and Eli Lilly, and grants from Novo Nordisk Foundation. Mette Julsgaard has received research grants from Takeda and the Novo Nordisk Foundation (grant no. NNF23OC0081717), has been on the advisory board of PharmaCosmos, has received consultation fee from Ferring and Takeda, and has received speaker’s fees from Tillotts Pharma, MSD, Ferring, and Takeda. Vibeke A ndersen has served as advisory board member for MSD (Merck). Søren Brunak has ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S, ALK abello A/S, Eli Lilly and Co and managing board memberships in Proscion A/S and Intomics A/S. Thorsten Brodersen’s spouse currently holds incentive stock options in LEO Pharma A/S. All other authors declare no conflict of interest. Ethical approval: CHB-CID:IBD studies will be conducted in accordance with the Declaration of Helsinki and has been approved by the National and the Capital, Central Denmark, and South Denmark Regional Committees on Health Research Ethics (NVK-1700407, H-18064178, M20100153, S-20120113, and S-20160124), as well as the Data Protection Agency of Capital (P-2019–99 and P-2022–876), Central (RM: J. 2010–41-4719) and Southern (RSD: 2008–58-035) Denmark. All individuals in CHB have been informed about their inclusion into the biobank and the use of their data for research. Concent for publication: ChatGPT ( https://chat.openai.com/ ) assisted copy editing was used and authors reviewed and revised the final version, taking full responsibility for the content of the publication.

Figures

Fig. 1
Fig. 1
CHB-CID:IBD genetic cohort structure and its linked clinical databases from all five healthcare regions of Denmark. a The links among sub-cohorts represent individuals recruited to multiple sub-cohorts. F: Females (bottom line), M: Males (upper line), CHB: Copenhagen Hospital Biobank, DBDS: Danish Blood Donor Study, the DRB: Danish Rheumatologic Biobank (The Biomarker Protocol), TARCID: Targeted Treatment of Chronic Inflammatory Disease. b A map of Denmark healthcare regions, adapted from Danmarks Statistik (https://www.dst.dk/)
Fig. 2
Fig. 2
First- and second-degree genetic relationship network among patients with IBD (IBD vs IBD) and among non-IBD controls (non-IBD vs non-IBD) confirmed the absence of large genetically related communities. Due to the figure size and contrast limitations, a small proportion of the two-member-only communities are shown. Colors are to distinguish the adjacent communities easily. Nodes represent individuals. Node sizes are based on the number of first- and/or second-degree genetic relationships, i.e., the larger the node, the greater the number of genetic relationships
Fig. 3
Fig. 3
First- and second-degree genetic relationship network between patients with IBD and non-IBD controls, i.e., IBD vs non-IBD genetic relationships. Due to the figure size and contrast limitations, a small proportion of the two-member-only communities are shown. Colors are to distinguish the adjacent communities easily. Nodes represent individuals. Node sizes are based on the number of first- and/or second-degree genetic relationships, i.e., the larger the node, the greater the number of genetic relationships
Fig. 4
Fig. 4
Percentage of individuals with different diagnoses and co-morbidities based on ICD10 classification. ICD10_I: Certain infectious and parasitic diseases, ICD10_II: Neoplasms, ICD10_III: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, ICD10_IV: Endocrine, nutritional and metabolic diseases, E66: Obesity, ICD10_V: Mental and behavioural disorders, ICD10_VI: Diseases of the nervous system, ICD10_VII: Diseases of the eye and adnexa, ICD10_VIII: Diseases of the ear and mastoid process, ICD10_IX: Diseases of the circulatory system, ICD10_X: Diseases of the respiratory system, ICD10_XI: Diseases of the digestive system (IBDs excluded), ICD10_XII: Diseases of the skin and subcutaneous tissue, ICD10_XIII: Diseases of the musculoskeletal system and connective tissue, ICD10_XIV: Diseases of the genitourinary system, ICD10_XV: Pregnancy, childbirth and the puerperium, ICD10_XVI: Certain conditions originating in the perinatal period, ICD10_XVII: Congenital malformations, deformations and chromosomal abnormalities, ICD10_XVIII: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified, ICD10_XIX_S00–S99: Injury, poisoning and certain other consequences of external causes, ICD10_XIX_T00–T98: Injury, poisoning and certain other consequences of external causes, ICD10_XX: External causes of morbidity and mortality, ICD10_XXI: Factors influencing health status and contact with health services, ICD10_XXII: Codes for special purposes, K12: Stomatitis and related lesions, K31: Other diseases of stomach and duodenum, K37: Unspecified appendicitis, K43: Ventral hernia, K52: Other noninfective gastroenteritis and colitis, K56: Paralytic ileus and intestinal obstruction without hernia, K58: Irritable bowel syndrome, K60: Fissure and fistula of anal and rectal regions, K62: Other diseases of anus and rectum, K63: Other diseases of intestine, K64: Haemorrhoids and perianal venous thrombosis, K91: Postprocedural disorders of digestive system, L40: Psoriasis, L41: Parapsoriasis, M05: Seropositive rheumatoid arthritis, M06: Other rheumatoid arthritis, M07: Psoriatic and enteropathic arthropathies, IBD: inflammatory bowel disease, CD: Crohn’s disease, and UC: Ulcerative colitis. UC, DC, and IBDs are based on minimum two type A and/or type B IBD diagnoses
See this image and copyright information in PMC

References

    1. Alatab S, Sepanlou SG, Ikuta K, Vahedi H, Bisignano C, Safiri S, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30. - PMC - PubMed
    1. Lewis JD, Parlett LE, Funk MLJ, Brensinger C, Pate V, Wu Q, et al. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States. Gastroenterology. 2023;165:1197-1205.e2. - PMC - PubMed
    1. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–78. - PubMed
    1. Moller FT, Andersen V, Wohlfahrt J, Jess T. Familial risk of inflammatory bowel disease: a population-based cohort study 1977–2011. Am J Gastroenterol. 2015;110:564–71. - PubMed
    1. Sazonovs A, Stevens CR, Venkataraman GR, Yuan K, Avila B, Abreu MT, et al. Large-scale sequencing identifies multiple genes and rare variants associated with Crohn’s disease susceptibility. Nat Genet. 2022;54:1275–83. - PMC - PubMed

LinkOut - more resources